Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06598059 · ClinicalTrials.gov registry record · NA

Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array

A NA study of Hearing Loss, sponsored by Cochlear.

Active
Registry status
NA
Development phase
56
Enrollment target
11
Study locations

NCT06598059 is a NA study of Hearing Loss that is active but no longer recruiting, run by Cochlear. The registered enrollment target is 56 participants, below the 6,120-participant average among 58 other Hearing Loss trials with a reported enrollment target (99% lower). The trial reports 11 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06598059, a NA study of Hearing Loss, is active but no longer recruiting, sponsored by Cochlear.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
56 participants
Enrollment target
11
Study locations

Study Summary

This clinical study will test a new type of cochlear implant known as CI632D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation and reduce tissue injury, which is common after any type of surgery. The goal is to learn if the dexamethasone in the CI632D implant lessens these reactions inside the ear following surgery and if this makes the implant work as well, or even better, in improving hearing than what would be expected with a standard cochlear implant. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve (the nerve that carries sound signals from the ear to the brain). The study participants will receive the CI632D experimental implant and will complete tests to see how well they are hearing and how well the implant is working.

Conditions Studied

Hearing Loss

Interventions

  • DRUG Dexamethasone
  • DEVICE Cochlear implant

Study Locations (11)

New York

  • New York Eye and Ear Infirmary - New York
  • NYU Langone Health - New York
  • Northwell Health Long Island Jewish Medical Center - New York

California

  • UCLA Medical Center - Los Angeles

Colorado

  • Rocky Mountain Ear Center - Englewood

Iowa

  • University of Iowa - Iowa City

Michigan

  • Henry Ford Health - Detroit

Missouri

  • Washington University - St Louis

Ohio

  • University Hospitals - Cleveland

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2025-01-03
Est. Completion 2026-09
Phase NA

Sponsor

Cochlear

34 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06598059

The ClinicalTrials.gov registry entry for NCT06598059 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,120-participant average among 58 other Hearing Loss trials with a reported enrollment target (99% lower). The listed sponsor is Cochlear, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hearing Loss appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.

NCT06598059 reports 11 study locations spanning 9 distinct geographic areas - top geographies include New York, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT06598059 about?

NCT06598059 is a clinical study titled "Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array". This clinical study will test a new type of cochlear implant known as CI632D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation and reduce tissue injury, which is common after any type of surgery. The goal is ...

What is the current status of trial NCT06598059?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 56 participants. The study started on 2025-01-03. Estimated completion is 2026-09.

What conditions does trial NCT06598059 study?

This clinical trial studies the following conditions: Hearing Loss.

What interventions are being tested in trial NCT06598059?

The interventions under investigation include: Dexamethasone (DRUG), Cochlear implant (DEVICE).

Who is sponsoring clinical trial NCT06598059?

This trial is sponsored by Cochlear, which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06598059 being conducted?

This trial has 11 study locations across California, Colorado, Iowa, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hearing Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hearing Loss

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.